NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) (“Inotek”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
“a placebo response that was… greater than that observed in Phase 2.”
On January 3, 2017, Inotek announced disappointing results for its Phase 3 pivotal trial of trabodenson for the treatment of primary open-angle glaucoma or ocular hypertension. The study failed to meet its primary endpoint due to “a placebo response that was… greater than that observed in Phase 2.” To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.